Drug Screening Market Size - By Component (Products, Services), Sample Type (Urine, Breath, Oral fluids), Drug Type (Cannabis, Opioids, Alcohol), End-use (Drug Testing Laboratories, Workplace, Law Enforcement Agencies, Hospitals) & Forecast 2023 - 2032

Drug Screening Market Size - By Component (Products, Services), Sample Type (Urine, Breath, Oral fluids), Drug Type (Cannabis, Opioids, Alcohol), End-use (Drug Testing Laboratories, Workplace, Law Enforcement Agencies, Hospitals) & Forecast 2023 - 2032

Drug Screening Market Size

Drug Screening Market size was valued at USD 6.2 billion in 2022 and is expected to reach USD 27.1 billion by 2032, registering a CAGR of 16.3% during the forecast period. Growth can be attributed to the surging consumption of drugs and alcohol across the globe that has accelerated the adoption of drug screening.
 

According to the World Drug Report 2021, drug use disorders were estimated to affect 36.3 million people worldwide in 2019. Thus, rising drug use disorder across the globe is expected to increase the product demand. Further, enforcement of stringent laws to curb drug and alcohol usage, strict laws on drug screening, and rising regulatory approvals of novel drug screening products are few of the factors that positively influencing the market revenue.
 

Drug screening test basically analyses biological samples such as urine, oral fluids, hair, and breath samples to determine the presence of drug abuse or its metabolites in patient’s body. Drug screening tests are used to determine whether a person is or was under the influence of drugs at any given time.
 

COVID-19 Impact

The COVID-19 pandemic had a significant impact on the drug screening market. This is attributed to a decrease in the number of people being tested because of an increase in the number of employees working from home and general concerns about COVID-19 safeguards. For instance, according to a recent survey conducted by the Current Consulting Group (CCG) in August 2021, about 21% of employers reported a decline of 61% or more in the number of drug tests undertaken on their employees during the pandemic. Similarly, as per research article published in Population Health Management, 2021, a significant decrease in the testing for prescription and illicit drugs was observed, with a weekly test volume decrease of 70%. Thus, decreased drug screening had a significant impact on the market during the pandemic.

Drug Screening Market Trend

The key factor driving the market is increased drug and alcohol consumption. For instance, as per the World Drug Report 2021 published by United Nations Office on Drugs and Crime (UNODC) in 2022, the number of people using drugs increased by 22%. The report also stated that, around 200 million people smoked cannabis in 2021, thereby increasing cannabis testing. Similarly, as per the Global Information System on Alcohol and Health (GISAH), in 2018 the worldwide total consumption was equal to 6.2 litres of pure alcohol per person in 15 years and older. Thus, the rising consumption of drugs and alcohol is expected to increase the demand for drug screening, thereby fuelling the overall market growth.
 

Drug Screening Market Restraint

Prohibition on workplace drug screening may hamper the market growth. For instance, Connecticut law generally prohibits private-sector employers from requiring employees to undergo random drug tests unless the state labour commissioner has designated their occupations as high-risk or safety-sensitive. Additionally, some countries such as Canada, Colombia, Argentina, Chile, and South Africa, regard workplace drug and alcohol testing to be a violation of employee privacy. Such bans in certain nations may restrict the adoption of drug and alcohol screening, hence may act as a restraint for the market value.
 

Drug Screening Market Analysis

By component, the drug screening market is classified into products and drug screening services. The product segment is further categorised into analytical instruments, rapid testing devices, and consumables. The product segment dominated the market in 2022 with a revenue share of 55.7%. Increasing launch of advanced drug screening products that provide improved solutions to make testing easy, accurate, and fast have accelerated the market trends. For instance, in May 2020, Psychemedics Corporation introduced a vaping panel to detect the use of Marijuana, CBD and Nicotine. Similarly, in May 2018, Omega Laboratories introduced Omega Hair 17-panel drug test offering tests for 45 different substances.
 

Based on sample type, the drug screening market is segmented into urine, breath, oral fluids, hair, and other sample types. The oral fluids sample is expected to register around USD 6.6 billion by 2032. The segment is projected to grow at the fastest rate during the forecast period. This high growth can be attributed to the fact that oral fluids are most used sample type to detect the presence of illicit substances and provide rapid and easy detection of drugs. Additionally, it is a quicker and less invasive sample to collect at the roadside. According to NCBI 2020 survey conducted for staff as well as patients concluded that oral fluid samples are preferred over urine samples as they help save time and maintain dignity.
 

By drug type, the drug screening market is segmented into alcohol, cannabis/marijuana, amphetamines, opioids, and other drug types. The cannabis/marijuana segment held largest market share of 35.1% in 2022. This can be attributed to high usage of cannabis drugs. For instance, as per the Center for Disease Control and Prevention (CDC), marijuana is the most used federally illegal drug in the U.S. accounting for nearly 48.2 million people used it at least once in 2019. Such increasing usage of cannabis/marijuana is expected to rise the demand for cannabis drug screening, thereby resulting in high segment progress.
 

The end-use in drug screening market is divided into drug testing laboratories, workplace, hospitals, law enforcement agencies, other end-users. Drug testing laboratories dominated the market and is expected to show considerable growth of 16.1% during the analysis period. Wide acceptance of drug testing laboratories is due to their accurate results and presence of trained personnel especially in developed countries for conducting effective tests. Also, drug testing laboratories can test for the presence of any illicit substance, which is not possible with rapid tests. Thus, benefits offered by drug testing laboratories will contribute to the market expansion.
 

North America is expected to hold significant share in the drug screening industry due to the serious problem related to high levels of alcohol intake. Also, the increasing consumption of illegal drugs, the availability of government funding to combat drug abuse, and the existence of strict rules in the country will propel the regional market growth. For instance, in April 2022, Quest Diagnostics, an American clinical laboratory performed drug testing and collected 11 million unidentifiable urine, hair, and oral fluid sample results between January and December 2021. The laboratory published data for collected samples in March 2022 and reported that, 7.5% of employees testing were positive for marijuana between January and December 2021. Hence, the rising consumption of drugs among people is expected to increase the demand for drug screening tests.
 

Drug Screening Market Share

Major market players operating in the drug screening market include

• Laboratory Corporation of America
• Quest Diagnostics
• Abbott Laboratories
• OraSure Technologies, Inc.
• Alfa Scientific Designs, Inc.
• Thermo Fisher Scientific Inc.
• Drägerwerk AG & Co. KGaA
• Lifeloc Technologies, Inc.
• Omega Laboratories, Inc.
• Premier Biotech, Inc.
• Psychemedics Corporation
• FHoffmann-La Roche Ltd
• Shimadzu Scientific Instruments.
•  Siemens Healthineers

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Drug Screening Industry News

• In April 2022, Saladax Biomedical, Inc acquired a patent portfolio for antipsychotic drug testing from Janssen Pharmaceutica NV. This intellectual property (IP) portfolio includes 17 patent families. This strategy placed the company in a premier position in the antipsychotic drug testing field.
   
• In April 2019, Thermo Fisher Scientific launched Thermo Scientific CEDIA Mitragynine (Kratom) Assay, its newest drugs of abuse test. The CEDIA Mitragynine (Kratom) assay can be run on commonly used clinical chemistry analyzers, allowing a broad spectrum of laboratorians to test for the presence of Kratom. This helped the company to widen its product portfolio.
   

The drug screening market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Component

• Products
  • Analytical instruments
    • Immunoassay analyzers
    • Chromatographic analyzers
    • Breath analyzers
  • Rapid testing devices
  • Consumables
• Drug screening services

By Sample Type

• Urine
• Breath
• Oral fluids
• Hair
• Other sample types

By Drug Type

• Alcohol
• Cannabis/Marijuana
• Amphetamines
• Opioids
• Other drug types

By End-use

• Drug testing laboratories
• Workplace
• Hospitals
• Law Enforcement Agencies
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA